Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JK-1201I vs Topotecan in Relapsed SCLC
NCT06581380Phase 3Not yet recruiting
- Sponsor
- JenKem Technology
- Start
- Sep 2024
- Primary completion
- Nov 2027
- Modality
- Polymer-based Nanoparticles, Small Molecules
01
Overview
A Phase 3 trial of JK-1201I in small cell lung cancer (SCLC), sponsored by JenKem Technology. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
JK-1201I
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06581380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06581380.